Strengths and Gaps in the Canadian Vaccine Landscape: a biotech perspective Nathalie Charland, PhD...
-
Upload
willa-preston -
Category
Documents
-
view
217 -
download
0
Transcript of Strengths and Gaps in the Canadian Vaccine Landscape: a biotech perspective Nathalie Charland, PhD...
Strengths and Gaps in the Canadian Vaccine
Landscape: a biotech perspective
Nathalie Charland, PhD
Sr. Director, Scientific liaisons
Vaccine Innovation Conference
May 26, 2015
© Medicago Inc.All rights reserved
2
®
• Numerous strengths in the Canadian vaccine industry: – Strong tradition of entrepreneurial spirit – Academic excellence– Rich history of innovation– Competitive costs– Accessible market
• BUT innovative vaccine candidates often left on a shelf or developed outside Canada
• One of the principal reasons why biotech companies struggle to bring a product to market: “Collaboration Gap”
– Translation of academic ideas into practical realities– GMP financing– Contacts– Flexibility re: opportunities
Canadian Vaccine Industry: attractive innovation but…
© Medicago Inc.All rights reserved
3
®
• A specialized industry– Relatively small (4% of pharma) but very dynamic– Interaction with Governments more important than in other markets
• Similar challenges– Capital intensive– High risk and long timelines– Financing (Canadian vs. US stock market)
• Need to build collaborative models– Multiple partners: Biotech/Pharmas, Public/Private, Not-for-Profit– Big Pharmas playing a more and more important role for smaller
companies for vaccine pipeline development
The challenge of vaccines for biotechs
© Medicago Inc.All rights reserved
4
®
• One of the few biotech companies that has succeeded in its growth process while remaining in Canada
• About 300 employees; labs and collaborations around the world
• Succeeded in bringing a Canadian innovation out of the laboratory
• Attracted international investments– $245M investment to build a production facility in Quebec City– Creation of 200 new high-skilled jobs by 2019
• Proceeding to the market at pace, allowing Canada to a return on of its investment
Medicago’s example
© Medicago Inc.All rights reserved
5
®
• Strengths:– Build on them
• Weaknesses– Collaborate
• Opportunities– Not all opportunities are equal
• Threats– Opportunities could be threats!
Know your strengths & weaknesses, choose your opportunities, identify threats
© Medicago Inc.All rights reserved
6
®
Founded in 1999 (licensed out from ULaval & Agriculture Canada)
2003: new CEO
Business model revision
From service provider to manufacturer of innovative products
Versatile platform with a vaccine focus
Access to highly qualified people
Breakthrough: – Discovery of plant-made virus-like particles
Medicago: a Canadian success story
© Medicago Inc.All rights reserved
7
®
Patent status
Granted
Pending
Ownership
Owned/Co-owned
In-licensed
211
414
235
390
• 52 different patented technologies (patent families)
• Protected by 625 patents (granted and pending)
•Technologies protected in 48 countries
Medicago patent portofolio
© Medicago Inc.All rights reserved
8
®
Gouvernments & agencies
Key elements to success – Partnerships
© Medicago Inc.All rights reserved
9
®
Universities & colleges
Key elements to success – Partnerships
Biotech companies or biopharma & research organizations
© Medicago Inc.All rights reserved
10
®
Focus– SWOT analysis (Strengths, Weaknesses, Opportunities, Threats)
Protect IP– Your bread & butter
Partnerships: – Collaborate early– Collaborate often– Be creative, opportunisitic in your collaborations!
Lessons learned by Medicago
Merci!Thank you!
Arigatō!